SCM
PLX icon

Sterling Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Sterling Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$606 Sell
260
-193
-43% -$409 ﹤0.01% 3206
2026
Q1 		$983 Hold
453
– – ﹤0.01% 3100
2025
Q4 		$815 Buy
453
+284
+168% +$581 ﹤0.01% 3153
2025
Q3 		$375 Buy
169
+1
+0.6% +$2 ﹤0.01% 3181
2025
Q2 		$249 Buy
+168
New +$344 ﹤0.01% 3222

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Sterling Capital Management's PLX Position: Q2 2026 in Review

Sterling Capital Management reduced its Protalix BioTherapeutics (PLX) stake by 43% in Q2 2026, selling an estimated $409 and leaving 260 shares worth $606. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

Sterling Capital Management first reported a position in PLX in Q2 2025 and has held it in 5 quarters since. The position peaked at $983 in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Sterling Capital Management held 260 shares of Protalix BioTherapeutics worth $606 as of Q2 2026.
  • Sterling Capital Management sold 193 Protalix BioTherapeutics shares in Q2 2026, an estimated $409.
  • Protalix BioTherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3206 holding.
  • Sterling Capital Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Protalix BioTherapeutics position peaked at $983 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.